C2N

Researchers Identify New Cost Savings and Accuracy of C2N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease

Retrieved on: 
Thursday, November 16, 2023
Research, Other Health, General Health, Pharmaceutical, Mental Health, Medical Devices, Clinical Trials, Science, Neurology, Biotechnology, Medical Supplies, Health, Other Science, Classification, Hypertension, Associate, Brain, Diagnosis, Deficit spending, RUO, APS2, CBD, Pathology, Ageing, AUC, Amyloid, Plasma, Disease, Peptide, CLIA, PSP, CSF, Non-fungible token, Patient, Research and development, LDT, MCI, FDA, Neuropathology, FTD, C2N, Physiology, Therapy, Dementia, Frontotemporal dementia, University, Corticobasal degeneration, Development, Clinical trial, Body mass index, Emilie Rissman, Biomarker, PET, Diabetes, Medical imaging, Medical device, Alzheimer's disease, Biostatistics, Medicine, Neuroscience

Dr. Joel Braunstein, CEO of C2N Diagnostics, said, “This year’s CTAD conference was a great success for C2N Diagnostics and the field as a whole.

Key Points: 
  • Dr. Joel Braunstein, CEO of C2N Diagnostics, said, “This year’s CTAD conference was a great success for C2N Diagnostics and the field as a whole.
  • Many independent researchers and collaborators presented important findings about our Precivity line of blood tests, affirming these clinical tools are aiding healthcare providers in the diagnosis and treatment of Alzheimer’s disease.
  • The tests are also helping researchers address key biological questions about the disease, who is at elevated risk, and how blood tests can help in everyday clinical practice.
  • The MTBR-tau fluid biomarker can be used in the diagnosis of AD, in disease staging, and in the development of tau-directed therapeutics.

C2N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF

Retrieved on: 
Thursday, August 17, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, General Health, Other Science, Science, Lund University, Laboratory developed test, Tulane University School of Medicine, LDT, Diagnosis, Chronic kidney disease, APS2, Cardiovascular disease, Pathology, Deficit spending, PET, Brain, Biomarker, Approximation error, Dementia, Amyloid, Plasma, Patient, C2N, Blood, AUC, Neurology, CSF, Ageing, AD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, FAAN, Food, Disease, Medical device, Medical imaging

C2N Diagnostics , a leader in advanced brain health diagnostics, today announced the release of the PrecivityAD2 blood test , a clinical care assay that meets the standard of care with currently available PET scans and cerebrospinal fluid tests.

Key Points: 
  • C2N Diagnostics , a leader in advanced brain health diagnostics, today announced the release of the PrecivityAD2 blood test , a clinical care assay that meets the standard of care with currently available PET scans and cerebrospinal fluid tests.
  • In a clinical validation study involving two independent cohorts totaling 583 patients with cognitive impairment using amyloid PET as the reference standard, the PrecivityAD2 blood test achieved an overall test performance statistic of 0.94 AUC and 88% accuracy.
  • The PrecivityAD2 blood test simultaneously quantifies specific plasma amyloid beta and tau peptide concentrations to calculate the Aβ42/40 Ratio and p-tau217/np-tau217(p-tau217 Ratio).
  • In this regard, the PrecivityAD2 blood test makes a significant contribution to the diagnosis of patients with Alzheimer’s disease.

C2N Diagnostics Announces Follow-on Investment from GHR Foundation as It Builds on Success in Novel Diagnostics to Aid in Alzheimer’s Disease Fight

Retrieved on: 
Thursday, February 16, 2023
Managed Care, Research, General Health, Philanthropy, Pharmaceutical, Medical Devices, Health Technology, Foundation, Clinical Trials, Science, Neurology, Biotechnology, Health, Diagnosis, PET, Patient, Family, Partnership, Deficit spending, Growth, GHR, Medical imaging, Medical device, C2N

C2N Diagnostics, LLC , a leader in advanced brain health diagnostics, today announced it has received a $15 million program-related investment from GHR Foundation .

Key Points: 
  • C2N Diagnostics, LLC , a leader in advanced brain health diagnostics, today announced it has received a $15 million program-related investment from GHR Foundation .
  • The investment will enable broader market access, expanded medical education, biomarker pipeline development, and infrastructure growth to facilitate global expansion.
  • GHR continues to believe that C2N’s technology will play a critical role in the early and accurate diagnosis of Alzheimer’s disease.
  • Having GHR Foundation by our side enables us to amplify our impact and global presence, thereby, bringing us one step closer to realizing our full ambitions.”

C2N Diagnostics Introduces the PrecivityAD2™ Blood Test

Retrieved on: 
Tuesday, November 29, 2022
Mental Health, Health, Neurology, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pathology, Doctor of Philosophy, Amyloid, Dementia, Approximation error, Diagnosis, Altruism, Peptide, PET, Apolipoprotein, Senior Consultant, Washington University School of Medicine, Health, AD, Patient, Lund University, Clinical trial, Ageing, Biomarker, Neurodegeneration, Radiation, BrightFocus Foundation, Disease, MD, Government budget balance, Research, Center for Epidemiologic Studies Depression Scale, Benefit, Cerebrospinal fluid, Apolipoprotein E, CSF, Plasma, Genotype, EU, APS2, Medical imaging, C2N, Neurology

C2N Diagnostics , LLC (C2N), a leader in advanced brain health diagnostics, today announced at the Clinical Trials on Alzheimers Disease (CTAD) 2022 EU/US Task Force on Blood Biomarkers its next generation test to aid in the diagnosis of Alzheimers disease (AD): the PrecivityAD2 blood test.

Key Points: 
  • C2N Diagnostics , LLC (C2N), a leader in advanced brain health diagnostics, today announced at the Clinical Trials on Alzheimers Disease (CTAD) 2022 EU/US Task Force on Blood Biomarkers its next generation test to aid in the diagnosis of Alzheimers disease (AD): the PrecivityAD2 blood test.
  • The PrecivityAD2 blood test is a significant innovation in the field of Alzheimers diagnostics.
  • The PrecivityAD2 test is our next-generation blood test, a natural extension of our prior two years of clinical experience with the PrecivityAD test.
  • C2N looks forward to sharing additional clinical data and details of the upcoming commercial launch of the PrecivityAD2 blood test as a validated laboratory developed test from our CLIA-certified and CAP-accredited laboratory in early 2023.

C₂N Diagnostics Partners with Grupo Fleury to Bring Pioneering Blood Tests to Brazil for Advancing Brain Health

Retrieved on: 
Wednesday, September 21, 2022
Medical Supplies, Biotechnology, Other Health, Health, General Health, Neurology, Mental Health, Other Science, Medical Devices, Research, Science, Reproduction, Center for Epidemiologic Studies Depression Scale, ASX, Neurodegeneration, Precision medicine, Memory, Marie Cassidy, Child care, Efficiency, Saliva, Disease, Entrepreneurship, City, Biomarker, Blood, Acquisition, Health, Partnership, SP, Diagnosis, HLS, Fleury, Davos, Patient, History, Physician, CEO, Standard of care, Pathology, Awareness, Plasma, Alzheimer's disease, Lists of diseases, Medical imaging, Medical device, Pharmaceutical industry, C2N

C2N Diagnostics , a leader in advanced brain health diagnostics, today announced it has entered a partnership with Grupo Fleury (BVMF: FLRY), one of Brazils leading healthcare companies, to bring blood-based tests that aid in early Alzheimers diagnosis to patient care in Brazil.

Key Points: 
  • C2N Diagnostics , a leader in advanced brain health diagnostics, today announced it has entered a partnership with Grupo Fleury (BVMF: FLRY), one of Brazils leading healthcare companies, to bring blood-based tests that aid in early Alzheimers diagnosis to patient care in Brazil.
  • Data from the Brazilian Ministry of Health estimate that there are 1.2 million cases of Alzheimer's disease in Brazil, most of them without an established diagnosis.
  • Grupo Fleury is a premier organization with an established history of providing high-quality healthcare services to patients throughout Brazil, including diagnostic and precision medicine.
  • C2N Diagnostics is a leader in advanced brain health diagnostics with a vision to bring Clarity Through Innovation.

Independent Research Finds Underlying Method for C2N’s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer’s Diagnoses

Retrieved on: 
Wednesday, September 14, 2022
Health, Biometrics, Genetics, Health Technology, Clinical Trials, Biotechnology, Center for Epidemiologic Studies Depression Scale, Neurodegeneration, Efficiency, Woman, Brain, Disease, Biomarker, Research, Blood, Washington University in St. Louis, Health, Alzheimer's disease, Diagnosis, Gold, Patient, PET, CEO, AAIC, MAA, Method, Dementia, Government budget balance, AUC, Mass spectrometry, Plasma, Technology transfer, Medical imaging, C2N

Currently available as a unique research tool in Alzheimers clinical studies, C2Ns p-tau217 ratio test is nearing completion of development as a clinical lab test that will help healthcare providers better diagnose Alzheimers disease, particularly when combined with amyloid beta (A) measures from C2Ns existing PrecivityAD clinical blood test .

Key Points: 
  • Currently available as a unique research tool in Alzheimers clinical studies, C2Ns p-tau217 ratio test is nearing completion of development as a clinical lab test that will help healthcare providers better diagnose Alzheimers disease, particularly when combined with amyloid beta (A) measures from C2Ns existing PrecivityAD clinical blood test .
  • The head-to-head comparison measured the diagnostic performance of 10 different tests that quantify plasma phosphorylated-tau concentrations, including the methods underlying C2Ns p-tau217 ratio blood test, to detect abnormal brain amyloid- status and predict future progression to Alzheimer's dementia.
  • The different tests compared in the round-robin study ranged from using mass spectrometry (MS)-based methods to immunoassays to detect one of three phosphorylated tau markers, including p-tau181, p-tau217, and p-tau231.
  • At this years AAIC annual meeting, the company reported its first clinical research experience combining its p-tau217 ratio blood test with its A 42/40 ratio blood test to identify amyloid pathology in individuals with cognitive impairment or dementia.

C2N’s New Blood Test Combining p-tau217 Ratio with Aβ42/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment

Retrieved on: 
Sunday, July 31, 2022
Research, General Health, Pharmaceutical, Consumer, Mental Health, Clinical Trials, Science, Biotechnology, Neurology, Seniors, Medical Supplies, Health, Pathology, Brain, Diagnosis, Data, Human, AUC, Protein, Research, Health, Biomarker, Government budget balance, PET, Alzheimer's disease, Conference, News, Disease, Neurodegeneration, Patient, Efficiency, IDEAS, Peptide, Phosphorylation, C2N, Center for Epidemiologic Studies Depression Scale, Cerebrospinal fluid, Medical imaging

The integrated score derived from the p-tau217 ratio and A42/40 ratio achieved an AUC performance of 0.96 and accuracy of 90% when compared with quantitative amyloid PET results.

Key Points: 
  • The integrated score derived from the p-tau217 ratio and A42/40 ratio achieved an AUC performance of 0.96 and accuracy of 90% when compared with quantitative amyloid PET results.
  • Dr. Joel Braunstein, CNs CEO, says, This news is an exciting and impactful milestone for our company and the Alzheimers field, in general.
  • We are committed to transforming the way in which patients around the world receive a timely and accurate diagnosis for their memory concerns.
  • Proper diagnosis is the first step in a patients journey to receive the care they need for their brain health.

C2N Achieves ISO 13485:2016 Certification; Latest Development for Leader in Brain Health Sector

Retrieved on: 
Tuesday, February 22, 2022
General Health, Mental Health, Medical Devices, Other Health, Health, Cortex, Certification, Medicare, Diagnosis, Accreditation, Peptide, Amyloid, CLIA, Efficiency, Center, Center for Medicare and Medicaid Innovation, Neurodegeneration, Duncan, CAP, ISO, Centers for Medicare & Medicaid Services, Disease, Clinical Laboratory Improvement Amendments, Accreditation Committee of Cambodia, Cortex Innovation Community, News, Brain, Government budget balance, College, Virtue, Patient, Technology, Apolipoprotein E, CEO, Health, Center for Epidemiologic Studies Depression Scale, Medical device, C2N

In late 2020 C2N launched the PrecivityAD test , an innovative blood test intended for use with patients with cognitive impairment.

Key Points: 
  • In late 2020 C2N launched the PrecivityAD test , an innovative blood test intended for use with patients with cognitive impairment.
  • The test aims to help health care providers better determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimers disease.
  • ISO 13485:2016 is designed to respond to the latest quality management system practices, including changes in technology and regulatory requirements and expectations.
  • C2N strives to provide exceptional laboratory services and products in the field of brain health.